Investigational drugs in sickle cell anemia

Expert Opinion on Investigational Drugs

Volumn 18, Issue 12, 2009, Pages 1817-1828

  Kotiah, Sandy D ^a   Ballas, Samir K ^a  

^a Cardeza Foundation   (United States)

Author keywords

Fetal hemoglobin; Gardos channel; Hemoglobin; Hemoglobin F induction; Hydroxycarbamide; Hydroxyurea; Hypomethylating agents; Investigational drugs; Nitric oxide; RBC dehydration; RBC rehydration sickle cell anemia; Sickle cell disease; Sickle hemoglobin

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ARGININE; AZACITIDINE; BOSENTAN; BUTYRIC ACID; CARBON MONOXIDE; CLOTRIMAZOLE; CORTICOSTEROID DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN F; HEMOXIN; HYDROXYUREA; LENALIDOMIDE; NICOSAN; NIPRISAN; NITRIC OXIDE; NIX 0699; PLACEBO; PLANT MEDICINAL PRODUCT; POLOXAMER; POMALIDOMIDE; PYROGLUTAMATE MAGNESIUM; SALAZOSULFAPYRIDINE; SILDENAFIL; SIMVASTATIN; TETRAHYDROBIOPTERIN; THALIDOMIDE; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VARESPLADIB;

ABDOMINAL PAIN; BLOOD CLOTTING; BLOOD TOXICITY; BLOOD VESSEL OCCLUSION; BONE MARROW SUPPRESSION; CELL ADHESION; CELL SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DNA METHYLATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSURIA; ENDOTHELIUM CELL; ERYTHROCYTE DEFORMABILITY; ERYTHROPOIESIS; EYELID EDEMA; HUMAN; INTRAVASCULAR HEMOLYSIS; ISCHEMIA; LEUKOCYTE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PHLEBOTOMY; POINT MUTATION; PULMONARY HYPERTENSION; REVIEW; SEIZURE; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VOMITING;

ADRENAL CORTEX HORMONES; ANEMIA, SICKLE CELL; CELL ADHESION; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; ERYTHROCYTES; FETAL HEMOGLOBIN; FIBRINOLYTIC AGENTS; HUMANS; PHOSPHOLIPASES A2; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 72249116345     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903247463     Document Type: Review

References (82)

1. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease. Am J Genet 2001;151:839-845
2. Gladwin M, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008;359:2254-2265
3. Johnson C, Tellen MJ. Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Haematologica 2008;93:481-485
4. Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol 2008;88:505-528
5. Fathallah H, Atweh G. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology 2006;1:58-62
6. Trompeter S, Roberts I. Heamoglobin F modulation in childhood sickle cell disease. Br J Hematol 2008;144:308-316
7. Serjeant G. Geographic heterogeneity of sickle cell disease. In: Disorders of Hemoglobin. Steinberg MH, Forget BG, Higgs DR, Nagel RL (editors). Cambridge University Press, Cambridge, UK 2001. p. 895-897
8. Farber MB, Koshy M, Kinney TR. Cooperative study of sickle cell disease: demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis 1985;38:495-505
9. Letvin NL, Linch DC, Beardsley GP. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984;310:869-873
10. Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989;32:104-111
11. Fibach E, Burke KP, Schechter AN, et al. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. Blood 1983;81:1630-1635
12. Kumkhaek C, Taylor J, Zhu J, et al. Fetal hemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anemia. Br J Haematol 2008;141:254-9
13. Cokic V, Andric S, Stojilkovic S, et al. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 2007;111:1117-23
14. Charache S, Terrin M, Moore R, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322
15. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on morbidity and mortality in adult sickle cell anemia. JAMA 2003;289:1645-1651
16. Hankins J, Aygun B. Pharmacotherapy in sickle cell disease-state of the art and future prospects. Br J Haematol 2009;145:1365-1377
17. Ballas SK, Marcolina MJ, Dover GJ, et al. Erythropoietic activity in patients with sickle cell anemia before and after treatment with hydroxyurea. Br J Haematol 1999;105:491-496
18. Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 1997;89:1078-1088
19. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes 2006;4:1-8
20. Saunthararajah Y, Lavelle D, Desimone J, et al. DNA hypo-methylating agents and sickle cell disease. Br J Hematol 2004;126:629-636
21. Desimone J, Heller P, Hall L, et al. 5-azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. PNAS 1982;78:4428-5231
22. Ley TJ, Desimone J, Noguchi CT, et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983;62:370-380
23. Dover GJ, Carache S, Boyer SH, et al. 5-Azacytidine increases HgF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood 1985;66:527-532
24. Fathallah H, Atweh GF. DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical applications. Blood Rev 2006;20:227-234
25. Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000;96:2379-2384
26. Desimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002;99:3905-3908
27. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2¢-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003;102:3865-3870
28. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:129-131
29. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-1797
30. Fathallah H, Weinberg RS, Galperin Y, et al. Role of epigenetic modification in normal globin gene regulation and butyrate mediated induction of fetal hemoglobin. Blood 2007;110:3391-3397
31. Dover GJ, Brusilow S, Carache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339-343
32. Resar LM, Segal JB, Fitzpatrick LK. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low dose sodium phenylbutyrate therapy. J Pediatr Hematol Oncol 2002;24:737-741
33. Selby R, Nisbet-Brown E, Basran RK, et al. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 1997;90:891-893
34. Ronndahl G, Monkemeyer S, Schulze S, et al. Novel valproic acid derivatives with hemoglobin F inducing activity. Am J Hematol 2006;81:374-376
35. Al-Khatti A, Veith RW, Papayannopoulou T, et al. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med 1987;317:415-420
36. Lavelle D, Molokie R, Ducksworth J, et al. Effects of hydroxyurea, stem cell factor and erythropoietin in combination on fetal hemoglobin in the baboon. Exp Hematol 2001;29:156-62
37. Goldberg MA, Brugnara C, Dover GJ, et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990;323:366-372
38. Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 2002;99:357-363
39. El-Hazmi MA, Al-Momen A, Warsy AS, et al. On the use of hydroxyurea/ erythropoietin combination therapy for sickle cell disease. Acta Haematol 1995;94:128-134
40. Aerbajinai W, Gao Z, Zhu J, et al. Thalidomide induces gamma-globin gene expression through reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007;110:2864-2871
41. Moutouh-De Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ stem cells. J Clin Invest 2008;118:248-258
42. Romero J, Suzuka S, Nagel RL, et al. Arginine supplementation of sickle transgenic mice reduces red cell density and gardos channel activity. Blood 2002;99:1103-1106
43. Nagel RL, Vichinsky E, Shah M, et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double blind study. Blood 1993;81:9-14
44. Singh P, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev 2007;4: CD003426
45. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996;97:1227-1234
46. Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008;111:3991-3997
47. Defranceschi L, Beuzard Y, Jouault H, et al. Modulation of erythrocyte potassium chloride cotransport, potassium content and density of magnesium dietary intake in transgenic SAD mice. Blood 1996;88:2738-2744
48. Defranceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997;100:1847-1852
49. Hankins JS, Wynn LW, Brugnara C, et al. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anemia. Br J Hematol 2007;140:80-85
50. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Hematol 2000;108:284-289
51. Lee M, Rosenzweig EB, Cairo MS. Pulmonary hypertension in sickle cell disease. Clin Adv Hematol Oncol 2007;5:645-654
52. Wood KC, Granger DL. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol 2007;34:926-932
53. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003;9:1498-1505
54. Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008;300:2638-2646
55. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Hematol 2000;111:498-500
56. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69
57. Styles LA, Kuypers K, Kesler K, et al. Arginine therapy does not benefit children with sickle cell anemia-results of the CSCC clinical trial consortium multi-institutional study. Blood 2007:110; ASH abstract 2252
58. Lopez BL, Kreshak AA, Morris CR, et al. L-arginine levels are diminished in adult vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003;120:532-534
59. Little JA, Hauser KP, Martyr SE, et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Hematol 2009;82:315-321
60. Kato G. Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite and apolipoprotein A-1. Hematology Am Soc Hematol Educ Program 2008;186-192
61. Lopez BL, Davis-Moon L, Ballas SK, et al. Sequential nitric oxide measurements during the emergency department treatment of acute vaso-occlusive sickle cell crisis. Am J Hematol 2000;64:15-19
62. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2004;289:1136-1142
63. Mack K, Mcgowan V, Tremonti C, et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br J Hematol 2008;142:971-978
64. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-453
65. Sabaa N, De Francheschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxia induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 2008;118:1924-1933
66. Benza RL. Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung 2008;186:247-254
67. Katusic ZS, D'Uscio LV, Cao S, et al. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 2009;30:48-54
68. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004;104:840-846
69. Solovey AA, Solovey AN, Harkness J, et al. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001;97:1937-1941
70. Adam-Graves P, Kedar A, Koshy M, et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 1997;90:2041-2046
71. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA 2001;286:2099-2106
72. Ballas SK, Files B, Luchtman-Jones L, et al. Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 2004;28:85-102
73. Imayu EW, Turner EA, Asakura T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br J Hematol 2002;118:337-343
74. Imayu EW, Turner EA, Asakura T. Niprisan (Nix-0699) improves the survival rate of transgenic sickle cell mice under acute hypoxic conditions. Br J Hematol 2003;122:1001-1008
75. Wambebe C, Khamofu H, Momoh JA, et al. Double blind, placebo controlled, randomized cross-over clinical trial of NIPRISAN in patients in sickle cell disorder. Phytomedicine 2001;8:252-261
76. Styles LA, Schalkwijk CG, Aarsman AJ, et al. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996;87:2573-2578
77. Ballas SK, Files B, Luchtman-Jones L, et al. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin 2005;30:165-170
78. Matsui SM, Varki A, Embury SH, et al. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002;100:3790-3796
79. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007;98:392-396
80. Strouse JJ, Takemoto CM, Keefer JR, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 2008;50:1006-1012
81. Ballas SK. Corticosteroids and sickle cell disease. J Natl Med Assoc 2009;101:283
82. Ballas SK. Hydration of sickle erythrocytes using a herbal extract (Pfaffia paniculata) in vitro. Br J Hematol 2000;111:359-362